Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageNeoGenomics, Inc., a Nevada corporation (referred to individually as the “Company” or collectively with its subsidiaries as “NeoGenomics,” “we,” “us,” or “our” in this Annual Report on Form 10-K) is the registrant for SEC reporting purposes.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Business segments
Q2 2026 · $201.7MThe company’s own SEC segment disclosure.
- Client Direct Billing$138.0M68%
- Commercial Insurance$36.3M18%
- Medicare And Other Governmental$27.4M14%
NeoGenomics, Inc. (NEO) reported revenue of $202M in Q2 2026 (quarter ended Jun 30, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 46% and net income of $2.2M (1.1% of revenue). For the full year FY2025, revenue was $727M (+10% year on year) and net income −$108M. Its largest product in Q2 2026 was Client Direct Billing at $138M, 68% of the disclosed total, well ahead of Commercial Insurance at 18%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Diagnostics & Research
Ranks #12 of 17 by Smart Score